Clinical trials: Glycogen Storage Disease Type III

Glycogen Storage Disease Type III

Safety, Tolerability, and Pharmacokinetics of UX053 in Patients With Glycogen Storage Disease Type III (GSD III)

• Terminated
• Age: 18 years and older
• Phase 1/2
• Results posted

The primary objective of the study is to evaluate the safety of UX053 in adults with Glycogen Storage Disease Type III (GSD III).

Trial name

NCT04990388

Testing

UX053, Antipyretic, H2 Blocker

Where

6 sites in United States, Italy and 1 more

Volunteers

9 people

Sponsor

Ultragenyx Pharmaceutical Inc